Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials.

Purpose: Anemia of chronic kidney disease (CKD) has traditionally been treated with recombinant human erythropoietin (rhEPO). Recently, daprodustat, a hypoxia-inducible factor prolyl-hydroxylase inhibitor, has also been shown to increase hematocrit. It remains unclear whether daprodustat or rhEPO sh...

Descripción completa

Detalles Bibliográficos

Publicado en:	European Journal of Clinical Pharmacology Vol. 78; no. 12; pp. 1867 - 1876
Autores principales:	Fatima, Kaneez, Ahmed, Warda, Fatimi, Asad Saulat, Mahmud, Omar, Mahar, Muhammad Umar, Ali, Ayesha, Aamir, Syed Roohan, Nasim, Muhammad Taha, Islam, Muhammad Bilal, Maniya, Muhammad Talha, Azim, Dua, Marsia, Shayan, Almas, Talal
Formato:	meta analysis research tables/charts Journal Article
Publicado:	Springer Nature Dec2022
Acceso en línea:	Ver este registro en EBSCOhost